Adaptive welcomes new board member Dr. Robert Hershberg, founder and CEO of VentiRx Pharmaceuticals.

Dr. Robert Hershberg

SEATTLE, WA, February 21, 2013 – Adaptive Biotechnologies Corporation, a leading provider of next generation sequencing assays for the adaptive immune system, announced today that Robert Hershberg, M.D., Ph.D., has joined the company’s board of directors. Dr. Hershberg will work closely with the board and management team to focus on corporate strategy and clinical development.

“Rob has been a respected leader and visionary in our industry for years,” said Adaptive CEO and President Chad Robins. “He’s been a pioneer in developing immunotherapeutic approaches to cancer and brings a wealth of experience in the clinical, regulatory and strategic planning disciplines. I look forward to working with him as we expand our offerings to clinical applications.”

Dr. Hershberg is a founder of VentiRx Pharmaceuticals and serves as Chief Executive Officer and member of the Board of Directors.

VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer. The company’s initial focus is developing novel small molecule product candidates targeting Toll-like receptor 8 (TLR8) for oncology and allergy.

Talking about his new board position, Dr. Hershberg said, “Adaptive is at the forefront of utilizing next generation techniques to profile the immune system. In particular, the company’s application of its technology to the diagnosis and prognosis of cancer patients is novel and exciting. I am optimistic that my background in immunology, oncology and immunotherapy will be helpful to Chad and his team, and will complement other members of Adaptive’s accomplished Board.”

Prior to VentiRx, Dr. Hershberg served as Senior Vice President and Chief Medical Officer at Dendreon Corporation, developing immunotherapy approaches for cancer. In this capacity, Dr. Hershberg led the Clinical, Regulatory, and Biometrics groups, focusing on the development of Provenge™ in metastatic prostate cancer.

Previously, Dr. Hershberg was an assistant professor at Harvard Medical School and an associate physician at the Brigham and Women’s Hospital in Boston, Massachusetts. He completed his undergraduate degree in molecular biology and M.D. at UCLA, and his Ph.D. in Biology at the Salk Institute.

Dr. Hershberg is clinically-boarded in Medical Genetics, and holds current clinical and research faculty positions at the University of Washington School of Medicine.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry. Adaptive operates a state-of-the-art high throughput centralized laboratory in Seattle that is CLIA certified and will be accepting clinical samples in 2013. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. In 2013, the company will introduce clonoSEQ (http://www.clonoseq.com),a clinical assay to measure and monitor minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today’s most common tests. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface.